Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $9.5900 (3.12%) ($9.5900 - $9.5900) on Fri. Feb. 19, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 8.73% (three month average) | RSI | 70 | Latest Price | $9.5900(3.12%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -4% a day on average for past five trading days. | Weekly Trend | HTBX advances 15.5% a week on average for past two weeks. | Market Behavior | Rotation from growth to value for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) ARKG(41%) XBI(41%) ARKK(37%) ACES(36%) IBB(36%) | Factors Impacting HTBX price | HTBX will decline at least -4.365% in a week (0% probabilities). VIXM(-26%) VXX(-22%) UUP(-15%) IGOV(-11%) XLU(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -4.365% (StdDev 8.73%) | Hourly BBV | -0.5 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | 5 Day Moving Average | $10.22(-6.16%) | 10 Day Moving Average | $10.23(-6.26%) | 20 Day Moving Average | $8.91(7.63%) | To recent high | -23.5% | To recent low | 82.3% | Market Cap | $1.055b | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |